Literature DB >> 16304370

Acute lymphoblastic leukemia: older patients and newer drugs.

Richard A Larson1.   

Abstract

Although the median age for adults with acute lymphoblastic leukemia (ALL) is older than 60 years, relatively few of these patients have been enrolled on prospective clinical trials. The presence of coexisting medical disorders and unfavorable cytogenetic and biological characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs. Selected patients have achieved remission and long-term survival following intensive chemotherapy. Preliminary data using several new agents that have shown promise for patients with ALL are described.

Entities:  

Mesh：

Year:  2005        PMID： 16304370     DOI： 10.1182/asheducation-2005.1.131

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  8 in total

1.  Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.

Authors:  Jonathan I Sive; Georgina Buck; Adele Fielding; Hillard M Lazarus; Mark R Litzow; Selina Luger; David I Marks; Andrew McMillan; Anthony V Moorman; Susan M Richards; Jacob M Rowe; Martin S Tallman; Anthony H Goldstone
Journal:  Br J Haematol       Date:  2012-03-13       Impact factor: 6.998

Review 2.  Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.

Authors:  Dan Douer
Journal:  Oncologist       Date:  2016-06-21

3.  Acute lymphocytic leukemia severity and mortality hospitalizations in the United States: A population-based study.

Authors:  Saanie Sulley; Saka Abimbola; Memory Ndanga
Journal:  Int J Health Sci (Qassim)       Date:  2022 May-Jun

4.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Authors:  Sabina Chiaretti; Antonella Vitale; Gianni Cazzaniga; Sonia Maria Orlando; Daniela Silvestri; Paola Fazi; Maria Grazia Valsecchi; Loredana Elia; Anna Maria Testi; Francesca Mancini; Valentino Conter; Geertruy te Kronnie; Felicetto Ferrara; Francesco Di Raimondo; Alessandra Tedeschi; Giuseppe Fioritoni; Francesco Fabbiano; Giovanna Meloni; Giorgina Specchia; Giovanni Pizzolo; Franco Mandelli; Anna Guarini; Giuseppe Basso; Andrea Biondi; Robin Foà
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

5.  Outcome of adult acute lymphoblastic leukemia in South East of iran (zahedan).

Authors:  Mohammad Ali Mashhadi; Mohhamad Mahdi Koushyar; Mehdi Mohammadi
Journal:  Iran J Cancer Prev       Date:  2012

6.  The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia.

Authors:  Abolghasem Allahyari; Seyed-Mehdi Hashemi; Fahimeh Nazemian; Mohammad Karimi; Mohammad-Reza Kazemi; Masoud Sadeghi
Journal:  Iran J Cancer Prev       Date:  2016-08-10

7.  Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK Pathways.

Authors:  Hongliang You; Dao Wang; Linlin Wei; Jiao Chen; Huanhuan Li; Yufeng Liu
Journal:  J Oncol       Date:  2022-02-21       Impact factor: 4.375

Review 8.  Management of older adults with acute lymphoblastic leukemia: challenges & current approaches.

Authors:  Yazeed Sawalha; Anjali S Advani
Journal:  Int J Hematol Oncol       Date:  2018-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.